Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF &
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survi
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
01:48pm, Thursday, 11'th Jun 2026
Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak.
Here's Why Incyte (INCY) is a Strong Value Stock
10:40am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chip Weakness, Middle East Concerns Drag Dow 549 Points
12:00pm, Wednesday, 10'th Jun 2026
Stocks are firmly lower as the chip stocks and Iran tensions weigh, while investors unpack this morning's CPI data
Incyte: I Am Moving From Hold To Buy
01:01am, Wednesday, 10'th Jun 2026
Incyte is upgraded to Buy as pipeline progress and improved EPS estimates offset Jakafi concentration risk. frontMIND Phase 3 data for Monjuvi in first-line DLBCL is promising, supporting potential ma
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
04:31pm, Tuesday, 09'th Jun 2026
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
02:08pm, Tuesday, 09'th Jun 2026
Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront.
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:42am, Tuesday, 09'th Jun 2026
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) M&A Call Transcript
10:58am, Monday, 08'th Jun 2026
Incyte Corporation (INCY) M&A Call Transcript
Here's Why Incyte (INCY) is a Strong Growth Stock
10:45am, Monday, 08'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeut
Incyte to Buy Vega Therapeutics For Up to $2 Billion
07:34am, Monday, 08'th Jun 2026
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
07:07am, Monday, 08'th Jun 2026
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipel
